Results 201 to 210 of about 927,052 (258)

Anti IL-17 in psoriasis

Expert Review of Clinical Immunology, 2019
Introduction: Psoriasis is a chronic, immune-mediated disease with significant associated comorbidities. Its pathogenesis is likely multifactorial, however, the interleukin-23/T helper 17 pathway has been identified as a critical axis in its pathogenesis.
Karen Ly, Mary P. Smith, Quinn Thibodeaux, Vidhatha Reddy, Wilson Liao, Tina Bhutani   +5 more
openaire   +2 more sources

Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis

Expert Opinion on Biological Therapy, 2018
Ankylosing spondylitis is the prototype of spondyloarthritis, a chronic inflammatory disease involving mainly the axial skeleton. The treatment strategy was, until now, restricted to NSAIDs and anti-TNF agents. Targeting Interleukin 17 is an emerging option with a currently available biologic agent, secukinumab.This paper reviews the available data ...
Daniel, Wendling, Frank, Verhoeven, Clément, Prati   +2 more
openaire   +2 more sources

Suppression of Experimental Autoimmune Uveoretinitis by Anti-IL-17 Antibody

Current Eye Research, 2009
To determine whether treatment with anti-IL-17 antibody could suppress the intraocular inflammation of experimental autoimmune uveoretinitis (EAU) in rats.Rats were immunized with interphotoreceptor retinoid binding protein (IRBP) R16 peptide and were treated with anti-IL-17 antibody. Clinical signs of inflammation and ocular histological sections were
Rui, Zhang, Jiang, Qian, Jie, Guo, Yi-Fei, Yuan, Kang, Xue   +4 more
openaire   +2 more sources

Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature

American Journal of Clinical Dermatology, 2022
Anti-interleukin (IL)-17 agents have shown excellent therapeutic efficacy in patients with psoriasis and are expected to be expanded to other chronic inflammatory diseases. However, patients receiving anti-IL-17 agents are at an increased risk of developing Candida infection, with some agents reported to increase the incidence in a dose-dependent ...
Mika, Yamanaka-Takaichi, Soha, Ghanian, David A, Katzka, Rochelle R, Torgerson, Afsaneh, Alavi   +4 more
openaire   +2 more sources

Brodalumab: The first anti-IL-17 receptor agent for psoriasis

Drugs of Today, 2017
Psoriasis is a chronic immune-mediated inflammatory skin disease in which the alteration of the interleukin-23 (IL-23)/IL-17 cytokine axis appears to be crucial from a pathogenetic perspective. This has been confirmed by the efficacy of monoclonal antibodies blocking IL-17A, such as secukinumab and ixekizumab.
openaire   +3 more sources

Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study

Journal of Autoimmunity, 2019
To evaluate the efficacy and safety of secukinumab in Behçet's patients with active mucocutaneous and articular manifestations refractory to previous treatments.We retrospectively evaluated 5 patients treated with the IL17-inhibitor secukinumab and diagnosed with Behçet according to ISG/ICBD criteria. All patients had active mucocutaneous and articular
Di Scala, Gerardo, Bettiol, Alessandra, Cojan, Rafaela Diana, Finocchi, Martina, Silvestri, Elena, Emmi, Giacomo   +5 more
openaire   +4 more sources

Anti-IL 17 biologics and pyoderma gangrenosum – therapeutic or causal?

Archives of Dermatological Research
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by pustules that rapidly progress into ulcers that commonly affect the lower limbs. Recently, successful treatment of PG has been reported with anti-IL 17 treatments. However, there have also been several reports of "paradoxical" induction of new PG lesions after use of IL-17 ...
Anna Wanzenberg, Elise Keshock, Naveed Sami   +2 more
openaire   +2 more sources

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification

Drugs of Today, 2021
Psoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis.
S, Magina, P, Filipe
openaire   +2 more sources

Anti IL-17 in rheumatolgy

2019
L’interleukine 17 (IL-17) est une cytokine clé dans l’inflammation chronique, via la voie Th17. Son action, couplée à celle du tumor necrosis factor (TNF), joue un rôle important dans la pathogénie de diverses maladies inflammatoires chroniques. En rhumatologie, la voie d’inhibition de l’IL17 est nouvellement approuvée dans le traitement du rhumatisme ...
openaire   +1 more source